Literature DB >> 2095567

Aluminum compounds used as adjuvants in vaccines.

S Shirodkar1, R L Hutchinson, D L Perry, J L White, S L Hem.   

Abstract

The structure of nine commercially manufactured aluminum-containing adjuvants was investigated by X-ray diffraction, infrared spectroscopy, transmission electron micrography, and energy dispersive spectrometry. Seven samples which were labeled as aluminum hydroxide were identified as boehmite, a crystalline aluminum oxyhydroxide [AlO(OH)]. However, the degree of crystallinity varied between the samples. Two samples which were labeled as aluminum phosphate were found to be amorphous aluminum hydroxyphosphate. Buffer anions and sulfate anions substitute for hydroxyls in the amorphous aluminum hydroxide formed by the in situ alum precipitation method. Finally, the aluminum-containing adjuvant in diphtheria and tetanus toxoid, U.S.P., produced by three manufacturers was characterized.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095567     DOI: 10.1023/a:1015994006859

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Structure of aluminum hydroxide gel II: aging mechanism.

Authors:  S L Nail; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1976-08       Impact factor: 3.534

2.  Comparison of IR spectroscopic analysis and X-ray diffraction of aluminum hydroxide gel.

Authors:  S L Nail; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1975-07       Impact factor: 3.534

3.  The structure of Schmidt's aluminium hydroxide gel.

Authors:  P SOUZA SANTOS; A VALLEJO-FREIRE; J PARSONS; J H WATSON
Journal:  Experientia       Date:  1958-09-15

4.  pH-stat titration of aluminum hydroxide gel.

Authors:  N J Kerkhof; R K Vanderlaan; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1977-11       Impact factor: 3.534

5.  Mode of action of immunological adjuvants: some physicochemical factors influencing the effectivity of polyacrylic adjuvants.

Authors:  J Kreuter; I Haenzel
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

Review 6.  Vaccine adjuvants.

Authors:  R Edelman
Journal:  Rev Infect Dis       Date:  1980 May-Jun

7.  Stabilization of aluminum hydroxide gel by specifically adsorbed carbonate.

Authors:  C J Serna; J C Lyons; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

8.  Adsorption of phosphate by aluminum hydroxycarbonate.

Authors:  J C Liu; J R Feldkamp; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

  8 in total
  22 in total

1.  Cross-linked protein crystals for vaccine delivery.

Authors:  N St Clair; B Shenoy; L D Jacob; A L Margolin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  The importance of surface charge in the optimization of antigen-adjuvant interactions.

Authors:  P M Callahan; A L Shorter; S L Hem
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

Review 3.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

4.  Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.

Authors:  Yue Zhang; Min Li; Fan Yang; Yufang Li; Zizheng Zheng; Xiao Zhang; Qingshan Lin; Ying Wang; Shaowei Li; Ningshao Xia; Jun Zhang; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

6.  Concentration determination of a recombinant vaccine antigen adsorbed onto an alum adjuvant by chemiluminescent nitrogen detection.

Authors:  John V Amari; Philip Levesque; Zhirui Lian; Trish Lowden; Uditha deAlwis
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

7.  Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum.

Authors:  R P Weissburg; P W Berman; J L Cleland; D Eastman; F Farina; S Frie; A Lim; J Mordenti; T T Nguyen; M R Peterson
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

8.  Characterization of antacid compounds containing both aluminum and magnesium. I. Crystalline powders.

Authors:  C L Peterson; D L Perry; H Masood; H Lin; J L White; S L Hem; C Fritsch; F Haeusler
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

9.  Disparate adjuvant properties among three formulations of "alum".

Authors:  Derek W Cain; Sergio E Sanders; Michael M Cunningham; Garnett Kelsoe
Journal:  Vaccine       Date:  2012-11-29       Impact factor: 3.641

10.  Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine.

Authors:  Amber L Clausi; Andrea Morin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.